Matthew Gall, Chief Financial Officer at iTeos Therapeutics, Inc. (ITOS), bought 5,000 shares at $26.09 ($130K) on 2021-06-16, disclosed to the SEC on 2021-06-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ITOS | SELL | 2021-12-28 | $232K | — | Filing → |